BioClavis
BioClavis is a Glasgow-based R&D and services lab operating the proprietary TempO-Seq targeted-sequencing platform under license from parent BioSpyder Technologies, offering molecular profiling, biomarker discovery, and companion diagnostic services to pharmaceutical, academic, and clinical research customers across the UK, Europe, and APAC.
- Company typePrivate
- Founded2017
- HeadquartersGlasgow, United Kingdom
- Headcount1–10
- GTM typeB2B
- OfferingServices
What BioClavis does
BioClavis, Ltd. is a Glasgow-based (Clydebank) privately held R&D and services laboratory founded in 2017 as a UK/European spin-out of US-based BioSpyder Technologies Inc., with shared founder/CEO Joel McComb across both entities. The company operates a single-site services model at Carus House, Clydebank, with a disclosed headcount of 1-10 employees and no disclosed external venture or private equity backing.
The company's core asset is the licensed TempO-Seq platform — a proprietary targeted-sequencing transcriptomic technology protected by an extensive multi-jurisdictional patent portfolio (US, UK, Europe, Singapore, Australia, Canada, India, New Zealand). TempO-Seq uses detector oligos that hybridize directly to expressed transcripts, eliminating the need for RNA extraction or reverse transcription and enabling profiling from difficult sample types including FFPE tissue (validated up to 30+ years old), crude cell lysates, whole blood, dried blood spots, and single cells. Product variants built on this core chemistry include TempO-LINC (single-cell, launched February 2024), TempO-SPan (high-throughput diagnostic testing including COVID-19), TempO-Seq FFPE, TempO-Seq Dried Blood Spot, and TempO-Seq miRNA, supported by modular pre-designed and custom gene panels and the TempO-Seq Portal cloud analysis tool.
BioClavis generates revenue primarily through professional services — molecular profiling, bioinformatics, and contract research for pharmaceutical drug discovery and companion diagnostic development, academic researchers, and clinical research organizations — supplemented historically by a £30/sample COVID-19 testing service launched December 2020. Distribution of TempO-Seq kits is handled via an authorized distributor network covering Spain, South Korea, Japan, Hong Kong, and Thailand, with BioSpyder Inc. serving North America. Strategic positioning is reinforced through participation in EU-funded consortia including RISK-HUNT3R (Horizon2020, 2021) and BRECISE (IHI/Horizon Europe, 2025).
BioClavis firmographics
Firmographics- Name
- BioClavis
- Legal name
- BioClavis, Ltd.
- Website
- https://bioclavis.co.uk
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- BioClavis is a Glasgow-based R&D and services lab operating the proprietary TempO-Seq targeted-sequencing platform under license from parent BioSpyder Technologies, offering molecular profiling, biomarker discovery, and companion diagnostic services to pharmaceutical, academic, and clinical research customers across the UK, Europe, and APAC.
- Ownership category
- akta.pro rank
BioClavis industry classification
Industry- Product category
- Genomics Services
- NAICS
- Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)
- akta.pro secondary industries
- Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB), Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)
Keywords
Where BioClavis is headquartered
LocationHeadquarters
- HQ city
- Glasgow
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
BioClavis business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales
Revenue model
- Molecular Profiling Services: Lab services providing TempO-Seq transcriptomic and genomic analysis for drug discovery, biomarker discovery, and precision medicine applications. Services include high-throughput transcriptomics, companion diagnostic development, and clinical research support.
- Bioinformatics Services: Additional analysis services including probe design, exploratory data analysis, differential gene expression analysis, machine learning classification, pathway analysis, and single-cell analysis.
- COVID-19 Testing Services: TempO-SPan based COVID-19 testing service offered to businesses and organizations at £30 per sample price point for routine screening.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Usage-based | Pay-as-you-go | COVID-19 Testing Service |
Go-to-market motion3 records
Distribution channels7 records
Marketing channels6 records
BioClavis product offering
Product offeringCore offering
BioClavis operates a Glasgow-based R&D and services laboratory that delivers TempO-Seq-based molecular profiling to pharmaceutical, academic, and clinical research customers. The company provides high-throughput transcriptomics, biomarker discovery, companion diagnostic development, and COVID-19 variant surveillance, packaged with cloud bioinformatics through the TempO-Seq Portal. Its offerings also include customizable gene-expression panels, dried blood spot and FFPE workflows, and the TempO-LINC single-cell platform.
Product overview
BioClavis offers a unified platform-plus-services model centered on TempO-Seq, a proprietary high-throughput targeted-sequencing transcriptomic technology that eliminates the need for RNA extraction or reverse transcription. The core TempO-Seq platform serves as the foundation for specialized assay products including TempO-Seq Dried Blood Spot (DBS), TempO-Seq FFPE, and TempO-Seq miRNA, each adapted for specific sample types. TempO-LINC extends the platform into single-cell genomics applications. The company provides modular assay panels (Whole Transcriptome, S1500+ Surrogate, PanCancer, and Custom) for multiple species, supported by bioinformatics services including probe design, differential expression analysis, and machine learning classification. Services span pharma (drug discovery, companion diagnostics), academic research, and clinical research applications. The ecosystem is unified by TempO-Seq Portal cloud-based data analysis software.
Differentiator
Problem solved
Functional benefit
Brands
- TempO-Seq: High-throughput targeted-sequencing transcriptomic/genomic platform technology for molecular analysis
- TempO-LINC
- TempO-Span
- TempO-Seq DBS
Products and services
- TempO-Seq Targeted, high-throughput transcriptomics platform using Detector Oligo chemistry to profile gene expression in a single assay, sold as a profiling service and kit to pharmaceutical and academic researchers.
- TempO-LINC Single-cell gene-expression profiling platform built on combinatorial split-pool barcoding, extending TempO-Seq chemistry to individual cells for pharma and academic customers.
- TempO-Span SARS-CoV-2 testing and variant surveillance panel built on TempO-Seq chemistry, offered as a per-sample COVID-19 testing service with results delivered through the TempO-Seq Portal.
- TempO-Seq Portal Cloud-based bioinformatics platform that performs QC and gene-expression analysis on TempO-Seq data and delivers standardized reporting to research and clinical customers.
- Pharma Services Dedicated TempO-Seq profiling service for pharmaceutical R&D teams, supporting drug discovery, mechanism-of-action studies, lead prioritization, and translational biomarker work.
- Academic Research Services TempO-Seq profiling services tailored for academic and university research groups, including customizable panels and cloud-based analysis via the TempO-Seq Portal.
- Clinical Research Services TempO-Seq clinical research service designed for clinical research organizations and translational sponsors needing validated profiling of FFPE and other clinical samples.
- Bioinformatics Services Bespoke bioinformatics and gene-expression analysis services delivered alongside TempO-Seq profiling projects, with reporting routed through the TempO-Seq Portal.
- Personalised Diagnostics Bespoke diagnostic development service that applies TempO-Seq chemistry to build companion and personalised diagnostics for pharmaceutical and clinical partners.
- High-Throughput Transcriptomics (HTTr) Scalable, high-volume gene-expression profiling service using TempO-Seq chemistry for customers requiring large numbers of samples and reproducible data turnaround.
Quantifiable outcome
- R2 = 0.97 correlation between FFPE and fresh frozen samples
- +4 more outcomes
Companies that use BioClavis
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles4 records
BioClavis technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature11 records
BioClavis partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- BRECISE Project ConsortiumcoreBioClavis joined the BRECISE project as an industry partner - a five-year research initiative co-funded by the Innovative Health Initiative (IHI) and Horizon Europe. The project focuses on precision oncology for prostate and bladder cancer using NGS-based multi-modality AI biomarkers. BioClavis contributes TempO-Seq for molecular analysis and biomarker identification.
- RISK-HUNT3R ConsortiumcoreBioClavis joined the Horizon2020-funded RISK-HUNT3R project alongside 36 partners including academic researchers, regulatory authorities, and safety scientists from Pharma and Cosmetics sectors. The five-year project aims to develop animal-free chemical safety assessment methods using TempO-Seq for high-throughput transcriptomics on in vitro cell models.
- BioSpyder Technologies Inc.coreBioClavis is a spin-out of US-based BioSpyder Technologies. The company leverages the proprietary TempO-Seq targeted-sequencing transcriptomic/genomic platform technology under license for precision diagnostics and drug discovery services. Joel McComb is CEO and founder of both companies.
- NHS and Academic ResearchersminorBioClavis maintains close collaborations with NHS and academic researchers to develop diagnostic solutions at the center of patient and healthcare system needs.
- Collaboration Partners (Various Fields)minorBioSpyder actively seeks collaborators in Liquid Biopsy, Toxicology/Metabolism, Oncology, Mental Health, Metabolic Diseases, Allergy, Host Defense, and Agriculture for TempO-Seq applications.
Scale indicators5 records
Recent moves8 records
Expansion highlights6 records
BioClavis competitors and assessment
Company assessmentBroad incumbents
- Eurofins Genomics: Part of Eurofins Scientific, one of the world's largest genomics services providers offering DNA/RNA sequencing, oligonucleotide synthesis, and bioinformatics. Comparable as a broader-scale genomics services lab serving pharma and academic customers with overlapping transcriptomics offerings.
- Illumina: Dominant sequencing platform vendor whose instruments underpin most RNA-seq and targeted sequencing workflows. Comparable as the underlying sequencing technology provider whose installed base defines the competitive context for TempO-Seq's targeted approach.
- Qiagen: Global provider of sample-preparation technologies and molecular diagnostics, including the QIAseq targeted sequencing portfolio. Comparable as a sample-tech and molecular diagnostics incumbent whose targeted-sequencing kits overlap with TempO-Seq use cases in pharma and clinical research.
- Bio-Rad Laboratories: Global life science tools provider offering ddPCR, single-cell platforms (e.g., ddSEQ), and molecular biology reagents. Comparable as a broader portfolio provider of molecular profiling tools with overlapping pharma and academic research customer segments.
Direct peers
- 10x Genomics: Leading single-cell genomics platform company offering Chromium and Visium products. Direct competitor to BioClavis's newly launched TempO-LINC single-cell platform with overlapping pharma and translational research customers.
- Standard BioTools (formerly Fluidigm): Developer of mass cytometry and single-cell genomics platforms including the Hyperion and Biomark systems. Direct competitor in high-throughput single-cell and targeted transcriptomics for pharma and academic research applications.
- BioSpyder Technologies: US-based parent company of BioClavis and original developer of the TempO-Seq platform. Directly comparable as the originating licensor and North American commercial arm of the same technology stack BioClavis delivers in the UK and Europe.
- Personalis: Cancer genomics services company offering tumor profiling and molecular diagnostic solutions including the NeXT Personal assay. Comparable as a services-led molecular profiling business serving pharma and clinical research customers with custom biomarker panels.
- NanoString Technologies: Developer of nCounter and GeoMx Digital Spatial Profiling platforms for targeted transcriptomics and gene expression. Direct competitor in the targeted-gene-expression space with overlapping pharma and academic customer use cases for biomarker discovery.
Emerging players
- Fluent BioSciences: Emerging single-cell transcriptomics company offering the PIPseq platform with a low-cost, scalable workflow. Comparable as a newer entrant targeting the same single-cell genomics and transcriptomics use cases that BioClavis is pursuing with TempO-LINC.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
BioClavis social profiles
Digital presenceBioClavis financial estimates
Financial estimateRevenue estimate
Valuation estimate
BioClavis leadership team
Management profileNumber of profiles
Profiles3 records
BioClavis funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BioClavis M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BioClavis
What does BioClavis do?
BioClavis operates a Glasgow-based R&D and services laboratory that delivers TempO-Seq-based molecular profiling to pharmaceutical, academic, and clinical research customers. The company provides high-throughput transcriptomics, biomarker discovery, companion diagnostic development, and COVID-19 variant surveillance, packaged with cloud bioinformatics through the TempO-Seq Portal. Its offerings also include customizable gene-expression panels, dried blood spot and FFPE workflows, and the TempO-LINC single-cell platform.
Is BioClavis a public or private company?
BioClavis is a private company. It is classified as corporate owned and is currently operating.
When was BioClavis founded?
BioClavis was founded in 2017. It employs 1 to 10 people.
Where is BioClavis based?
BioClavis is headquartered in Glasgow, United Kingdom, in the Europe region.
How does BioClavis make money?
Three revenue lines are on record. Molecular Profiling Services are the primary driver. The others are bioinformatics Services and COVID-19 Testing Services.
Who are BioClavis's main competitors?
Broad incumbents on record are Eurofins Genomics, Illumina, Qiagen and Bio-Rad Laboratories. Direct peers are 10x Genomics, Standard BioTools (formerly Fluidigm), BioSpyder Technologies, Personalis and NanoString Technologies. Fluent BioSciences is listed as an emerging player.
Does BioClavis have an API?
No public API is recorded for BioClavis.
What industry is BioClavis in?
BioClavis's product category is Genomics Services. Its primary akta.pro industry code is HLAFAMAE, Molecular Diagnostics & Genomics Laboratories, with a secondary code of HLAGAEAB, Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry). Its NAICS code is 621511 and its SIC code is 8071.